Holen Sie sich die Stockscreener-App
1.14
3.39%
-0.04
Handel nachbörslich:
1.16
0.02
+1.75%
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
BioXcel Therapeutics Inc. (BX20.SG) Analyst insights, Price targets and Recommendations - sg.finance.yahoo.com
BTAI Should I Buy - Intellectia AI
BTAI: HC Wainwright & Co. Lowers Price Target, Maintains Buy Rat - GuruFocus
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution By Investing.com - Investing.com Australia
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution - Investing.com
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
FDA accepts BioXcel filing for at-home agitation treatment By Investing.com - Investing.com South Africa
FDA accepts BioXcel filing for at-home use of agitation drug By Investing.com - Investing.com South Africa
BTAI Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel Therapeutics, Inc. (BTAI) Stock Price, News, Quote & History - ca.finance.yahoo.com
BioXcel Therapeutics, Inc. (BTAI) stock price, news, quote and history - Yahoo Finance Singapore
FDA accepts BioXcel filing for at-home use of agitation drug - Investing.com Australia
BTAI: FDA Reviews BioXcel's Home Use Application for Igalmi - GuruFocus
FDA Accepts BioXcel sNDA for At-Home IGALMI Use - TipRanks
BioXcel Therapeutics Announces Food and Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - marketscreener.com
FDA accepts BioXcel Therapeutics application for IGALMI in at-home agitation treatment - Investing.com UK
FDA accepts BioXcel filing for at-home agitation treatment - Investing.com
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - The Manila Times
BioXcel seeks first at-home FDA-approved agitation treatment - stocktitan.net
BioXcel Therapeutics (BTAI) gets FDA review date for IGALMI at-home agitation use - stocktitan.net
BTAI.O Forecast — Price Prediction for 2026. Should I Buy BTAI.O? - Intellectia AI
BTAI.O PE Ratio & Valuation, Is BTAI.O Overvalued - Intellectia AI
BTAI.O Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - Bitget
Certain Common Stock of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Warrants of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - MarketScreener
BTAI SEC FilingsBioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
Why are BioXcel Therapeutics shares down Friday? - MSN
Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI) - The Globe and Mail
Qatar Investment Authority (BTAI) reports 156,066 BioXcel shares owned - stocktitan.net
Pharvaris (NASDAQ:PHVS) versus BioXcel Therapeutics (NASDAQ:BTAI) Critical Comparison - Defense World
Free cash flow per share of BioXcel Therapeutics, Inc. – FWB:BX20 - TradingView
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks - Yahoo Finance
SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BioXcel Therapeutics, Inc. 2025 Annual Report Highlights: Business Overview, Risk Factors, and Forward-Looking Statements - Minichart
BioXcel Therapeutics Inc. R (BX20.F) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada
BioXcel Therapeutics (NASDAQ: BTAI) bets on BXCL501 at-home use - stocktitan.net
BioXcel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioXcel Therapeutics reports Q4 & FY2025 results; FY revenue $642k, net loss $69.9M - TradingView
BTAI: IGALMI at-home sNDA submitted; revenue down, cost controls in place, large market targeted - TradingView
BioXcel (NASDAQ: BTAI) flags going concern as IGALMI label bid advances - Stock Titan
AI-driven biopharma firm BioXcel Therapeutics posts lower-than-expected Q4 loss on reduced SG&A costs - TradingView
Earnings Scheduled For March 27, 2026 - Benzinga
BRIEF-BioXcel Therapeutics Q4 Basic EPS USD -0.58 Vs. IBES Estimate USD -0.75 - TradingView
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting - ChartMill
BioXcel Therapeutics 2025 10-K: Revenue $0.642M, Net Loss $(69.897)M - TradingView
ETF Watch: Is BioXcel Therapeutics Inc benefiting from interest rate changes2026 Highlights & Target Return Focused Picks - baoquankhu1.vn
BioXcel Therapeutics $9.75M Class Action Settlement - Claim Depot
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc. - GlobeNewswire Inc.
Why did BTAI stock surge 20% in pre-market today? - MSN
If You Invested $1,000 in Bioxcel Therapeutics Inc (BTAI) - stocktitan.net
Stock Ratings | Baird Bank raises CRCL's price target to $138; Rodman & Renshaw initiates coverage of BTAI with a "buy" recommendation and a $17 price target, representing a potential upside of 882.66%. - Sahm
Buyout Rumor: Whats BioXcel Therapeutics Incs historical return2026 Trade Ideas & High Accuracy Swing Entry Alerts - baoquankhu1.vn
BioXcel Therapeutics Inc (BTAI) Stock Price, Quote, News & History - Benzinga
BioXcel Therapeutics stock initiated with buy rating at Rodman By Investing.com - ca.investing.com
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):